SCHEMBL16239689

SCHEMBL16239689

Cc1cccc(Nc2ccc(NC(=O)O)cc2)c1N

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK13 O15264 4/20 0.47
MAPK12 P53778 4/20 0.47
MAPK11 Q15759 4/20 0.47
MAPK14 Q16539 4/20 0.47
SIRT2 Q8IXJ6 3/20 0.44
NPC1 O15118 3/20 0.44
RAB9A P51151 2/20 0.44
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
DDX3X O00571 2/20 0.42
MAPT P10636 5/20 0.42
GAA P10253 3/20 0.42
GFER P55789 2/20 0.42
POLB P06746 1/20 0.42
LMNA P02545 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
CASP3 P42574 1/20 0.41
SENP7 Q9BQF6 1/20 0.41
HTT P42858 1/20 0.40
KDM4E B2RXH2 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16238956 0.84 HTT (0.44) MAPK13MAPK12MAPK11MAPK14SIRT2
SCHEMBL11901463 0.83 MAPT (0.55) MAPK13MAPK12MAPK11MAPK14NPC1
SCHEMBL28392058 0.82 BRD4 (0.45) MAPK13MAPK12MAPK11MAPK14
SCHEMBL16239629 0.81 MAPK13 (0.40) MAPK13MAPK12MAPK11MAPK14SIRT2
SCHEMBL1625533 0.75 TDP1 (0.42) MAPK13MAPK12MAPK11MAPK14SIRT2
SCHEMBL17947388 0.74 CD44 (0.43) MAPK13MAPK12MAPK11MAPK14NPC1
SCHEMBL16238935 0.74 MAPT (0.44) MAPK14NPC1RAB9AKMT2AMAPT
SCHEMBL1708324 0.73 CYP3A4 (0.65) NPC1RAB9AMEN1KMT2AMAPT
SCHEMBL14972592 0.73 METAP2 (0.40) MAPK14NPC1RAB9AMEN1KMT2A
Hydrochloric Acid SCHEMBL28755176 0.73 ALDH1A1 (0.63) NPC1RAB9AMEN1KMT2ADDX3X

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11434207-B2 P2X4 receptor antagonist NIPPON CHEMIPHAR CO., LTD (JP) 2022-09-06 US disclosed
US-20200223806-A1 P2X4 RECEPTOR ANTAGONIST NIPPON CHEMIPHAR CO., LTD (JP) 2020-07-16 US disclosed
US-10633349-B2 P2X4 receptor antagonist NIPPON CHEMIPHAR CO., LTD (JP) 2020-04-28 US disclosed
US-20180201587-A1 P2X4 RECEPTOR ANTAGONIST NIPPON CHEMIPHAR CO., LTD (JP) 2018-07-19 US disclosed
US-9969700-B2 P2X4 receptor antagonist NIPPON CHEMIPHAR CO., LTD. (JP) 2018-05-15 US disclosed
EP-2803662-B1 P2X4 RECEPTOR ANTAGONIST NIPPON CHEMIPHAR CO (JP) 2017-03-01 EP disclosed
US-20160280667-A1 P2X4 RECEPTOR ANTAGONIST NIPPON CHEMIPHAR CO., LTD (JP) 2016-09-29 US disclosed
US-9382236-B2 P2X4 receptor antagonist NIPPON CHEMIPHAR CO., LTD (JP) 2016-07-05 US disclosed
US-20140357858-A1 P2X4 RECEPTOR ANTAGONIST NIPPON CHEMIPHAR CO., LTD (JP) 2014-12-04 US disclosed
EP-2803662-A1 P2X4 RECEPTOR ANTAGONIST Nippon Chemiphar Co., Ltd. (JP) 2014-11-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160280667-A1 P2X4 RECEPTOR ANTAGONIST P2RX7, P2RX1, P2RX2 MAPK13 1635/4885MAPK12 1672/4885MAPK11 1482/4885
US-20140357858-A1 P2X4 RECEPTOR ANTAGONIST P2RX7, P2RX1, P2RX2 MAPK13 1602/4885MAPK12 1642/4885MAPK11 1500/4885
US-20200223806-A1 P2X4 RECEPTOR ANTAGONIST P2RX7, P2RX1, P2RX2 MAPK13 1602/4885MAPK12 1642/4885MAPK11 1500/4885
US-11434207-B2 P2X4 receptor antagonist P2RX7, P2RX1, P2RX2 MAPK13 1602/4885MAPK12 1642/4885MAPK11 1500/4885
US-10633349-B2 P2X4 receptor antagonist P2RX7, P2RX1, P2RX2 MAPK13 1602/4885MAPK12 1642/4885MAPK11 1500/4885
US-20180201587-A1 P2X4 RECEPTOR ANTAGONIST P2RX7, P2RX1, P2RX2 MAPK13 1602/4885MAPK12 1642/4885MAPK11 1500/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.